{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T01:15:25Z","timestamp":1791422125693,"version":"4.3.3"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,9,11]],"date-time":"2013-09-11T00:00:00Z","timestamp":1378857600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Malignant mesotheliomas (MMs) are chemoresistant tumors related to exposure to asbestos fibers. The long latency period of MM (30-40 yrs) and heterogeneity of tumor presentation make MM difficult to diagnose and treat at early stages. Currently approved second-line treatments following surgical resection of MMs include a combination of cisplatin or carboplatin (delivered systemically) and pemetrexed, a folate inhibitor, with or without subsequent radiation. The systemic toxicities of these treatments emphasize the need for more effective, localized treatment regimens.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Acid-prepared mesoporous silica (APMS) microparticles were loaded with doxorubicin (DOX) and modified externally with a mesothelin (MB) specific antibody before repeated intraperitoneal (IP) injections into a mouse xenograft model of human peritoneal MM. The health\/weight of mice, tumor volume\/weight, tumor necrosis and cell proliferation were evaluated in tumor-bearing mice receiving saline, DOX high (0.2 mg\/kg), DOX low (0.05 mg\/kg), APMS-MB, or APMS-MB-DOX (0.05 mg\/kg) in saline.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Targeted therapy (APMS-MB-DOX at 0.05 mg\/kg) was more effective than DOX low (0.05 mg\/kg) and less toxic than treatment with DOX high (0.2 mg\/kg). It also resulted in the reduction of tumor volume without loss of animal health and weight, and significantly decreased tumor cell proliferation. High pressure liquid chromatography (HPLC) of tumor tissue confirmed that APMS-MB-DOX particles delivered DOX to target tissue.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Data suggest that targeted therapy results in greater chemotherapeutic efficacy with fewer adverse side effects than administration of DOX alone. Targeted microparticles are an attractive option for localized drug delivery.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2407-13-400","type":"journal-article","created":{"date-parts":[[2013,9,11]],"date-time":"2013-09-11T16:21:36Z","timestamp":1378916496000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Microspheres targeted with a mesothelin antibody and loaded with doxorubicin reduce tumor volume of human mesotheliomas in xenografts"],"prefix":"10.1186","volume":"13","author":[{"given":"Sherrill L","family":"Macura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy L","family":"Steinbacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian B","family":"MacPherson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa J","family":"Lathrop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mutlay","family":"Sayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jedd M","family":"Hillegass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacie L","family":"Beuschel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy N","family":"Perkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Page C","family":"Spiess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"van der Vliet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly J","family":"Butnor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arti","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilyn","family":"Wadsworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher C","family":"Landry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooke T","family":"Mossman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,9,11]]},"reference":[{"issue":"26","key":"4042_CR1","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1056\/NEJM198906293202604","volume":"320","author":"BT Mossman","year":"1989","unstructured":"Mossman BT, Gee JB: Asbestos-related diseases. N Engl J Med. 1989, 320 (26): 1721-1730. 10.1056\/NEJM198906293202604.","journal-title":"N Engl J Med"},{"issue":"24","key":"4042_CR2","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1056\/NEJM198206173062403","volume":"306","author":"JE Craighead","year":"1982","unstructured":"Craighead JE, Mossman BT: The pathogenesis of asbestos-associated diseases. N Engl J Med. 1982, 306 (24): 1446-1455. 10.1056\/NEJM198206173062403.","journal-title":"N Engl J Med"},{"issue":"5","key":"4042_CR3","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1080\/00039896.1983.10544004","volume":"38","author":"K Browne","year":"1983","unstructured":"Browne K: Asbestos-related mesothelioma: epidemiological evidence for asbestos as a promoter. Arch Environ Health. 1983, 38 (5): 261-266. 10.1080\/00039896.1983.10544004.","journal-title":"Arch Environ Health"},{"issue":"6 Suppl 18","key":"4042_CR4","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1053\/sonc.2002.37469","volume":"29","author":"NJ Vogelzang","year":"2002","unstructured":"Vogelzang NJ: Emerging insights into the biology and therapy of malignant mesothelioma. Semin Oncol. 2002, 29 (6 Suppl 18): 35-42.","journal-title":"Semin Oncol"},{"issue":"5","key":"4042_CR5","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s00280-008-0800-0","volume":"63","author":"K Van der Speeten","year":"2009","unstructured":"Van der Speeten K, Stuart OA, Mahteme H, Sugarbaker PH: A pharmacologic analysis of intraoperative intracavitary cancer chemotherapy with doxorubicin. Cancer Chemother Pharmacol. 2009, 63 (5): 799-805. 10.1007\/s00280-008-0800-0.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"4042_CR6","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/COC.0b013e3180684181","volume":"31","author":"ME Hesdorffer","year":"2008","unstructured":"Hesdorffer ME, Chabot JA, Keohan ML, Fountain K, Talbot S, Gabay M, Valentin C, Lee SM, Taub RN: Combined resection, intraperitoneal chemotherapy, and whole abdominal radiation for the treatment of malignant peritoneal mesothelioma. Am J Clin Oncol. 2008, 31 (1): 49-54. 10.1097\/COC.0b013e3180684181.","journal-title":"Am J Clin Oncol"},{"issue":"6","key":"4042_CR7","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.ctrv.2011.10.006","volume":"38","author":"P Mirarabshahii","year":"2012","unstructured":"Mirarabshahii P, Pillai K, Chua TC, Pourgholami MH, Morris DL: Diffuse malignant peritoneal mesothelioma\u2013An update on treatment. Cancer Treat Rev. 2012, 38 (6): 605-612. 10.1016\/j.ctrv.2011.10.006.","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"4042_CR8","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1053\/sonc.2002.30236","volume":"29","author":"PH Sugarbaker","year":"2002","unstructured":"Sugarbaker PH, Acherman YI, Gonzalez-Moreno S, Ortega-Perez G, Stuart OA, Marchettini P, Yoo D: Diagnosis and treatment of peritoneal mesothelioma: The Washington Cancer Institute experience. Semin Oncol. 2002, 29 (1): 51-61.","journal-title":"Semin Oncol"},{"key":"4042_CR9","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/j.1749-6632.2010.05554.x","volume":"1203","author":"JM Hillegass","year":"2010","unstructured":"Hillegass JM, Shukla A, Lathrop SA, MacPherson MB, Beuschel SL, Butnor KJ, Testa JR, Pass HI, Carbone M, Steele C, Mossman BT: Inflammation precedes the development of human malignant mesotheliomas in a SCID mouse xenograft model. Ann N Y Acad Sci. 2010, 1203: 7-14. 10.1111\/j.1749-6632.2010.05554.x.","journal-title":"Ann N Y Acad Sci"},{"issue":"9","key":"4042_CR10","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1369\/0022155412452567","volume":"60","author":"SL Macura","year":"2012","unstructured":"Macura SL, Hillegass JM, Steinbacher JL, MacPherson MB, Shukla A, Beuschel SL, Perkins TN, Butnor KJ, Lathrop MJ, Sayan M, Hekmatyar K, Taatjes DJ, Kauppinen RA, Landry CC, Mossman BT: A multifunctional mesothelin antibody-tagged microparticle targets human mesotheliomas. J Histochem Cytochem. 2012, 60 (9): 658-674. 10.1369\/0022155412452567.","journal-title":"J Histochem Cytochem"},{"key":"4042_CR11","volume-title":"Mesoporous silicates and method of making same","author":"KW Gallis","year":"2002","unstructured":"Gallis KW, Landry CC: Mesoporous silicates and method of making same. 2002, US Patent 6,334,988"},{"issue":"1","key":"4042_CR12","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1021\/am2013008","volume":"4","author":"K Cheng","year":"2012","unstructured":"Cheng K, El-Boubbou K, Landry CC: Binding of HIV-1 gp120 glycoprotein to silica nanoparticles modified with CD4 glycoprotein and CD4 peptide fragments. ACS Appl Mater Interfaces. 2012, 4 (1): 235-243. 10.1021\/am2013008.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"9","key":"4042_CR13","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1021\/am100530t","volume":"2","author":"K Cheng","year":"2010","unstructured":"Cheng K, Blumen SR, MacPherson MB, Steinbacher JL, Mossman BT, Landry CC: Enhanced uptake of porous silica microparticles by bifunctional surface modification with a targeting antibody and a biocompatible polymer. ACS Appl Mater Interfaces. 2010, 2 (9): 2489-2495. 10.1021\/am100530t.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"3","key":"4042_CR14","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1165\/rcmb.2006-0319OC","volume":"36","author":"SR Blumen","year":"2007","unstructured":"Blumen SR, Cheng K, Ramos-Nino ME, Taatjes DJ, Weiss DJ, Landry CC, Mossman BT: Unique uptake of acid-prepared mesoporous spheres by lung epithelial and mesothelioma cells. Am J Respir Cell Mol Biol. 2007, 36 (3): 333-342. 10.1165\/rcmb.2006-0319OC.","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"Suppl 1","key":"4042_CR15","first-page":"133","volume":"20","author":"DB Warheit","year":"2001","unstructured":"Warheit DB: Inhaled amorphous silica particulates: What do we know about their toxicological profiles?. J Environ Pathol Toxicol Oncol. 2001, 20 (Suppl 1): 133-141.","journal-title":"J Environ Pathol Toxicol Oncol"},{"issue":"1","key":"4042_CR16","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1073\/pnas.93.1.136","volume":"93","author":"K Chang","year":"1996","unstructured":"Chang K, Pastan I: Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA. 1996, 93 (1): 136-140. 10.1073\/pnas.93.1.136.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"4042_CR17","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1158\/1078-0432.CCR-06-2161","volume":"13","author":"M Ho","year":"2007","unstructured":"Ho M, Bera TK, Willingham MC, Onda M, Hassan R, FitzGerald D, Pastan I: Mesothelin expression in human lung cancer. Clin Cancer Res. 2007, 13 (5): 1571-1575. 10.1158\/1078-0432.CCR-06-2161.","journal-title":"Clin Cancer Res"},{"key":"4042_CR18","first-page":"20","volume":"7","author":"R Hassan","year":"2007","unstructured":"Hassan R, Ebel W, Routhier EL, Patel R, Kline JB, Zhang J, Chao Q, Jacob S, Turchin H, Gibbs L, Phillips MD, Mudali S, Iacobuzio-Donahue C, Jaffee EM, Moreno M, Pastan I, Sass PM, Nicolaides NC, Grasso L: Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin. Cancer Immun. 2007, 7: 20-","journal-title":"Cancer Immun"},{"issue":"10","key":"4042_CR19","doi-asserted-by":"publisher","first-page":"9190","DOI":"10.1074\/jbc.M312372200","volume":"279","author":"A Rump","year":"2004","unstructured":"Rump A, Morikawa Y, Tanaka M, Minami S, Umesaki N, Takeuchi M, Miyajima A: Binding of ovarian cancer antigen CA125\/MUC16 to mesothelin mediates cell adhesion. J Biol Chem. 2004, 279 (10): 9190-9198. 10.1074\/jbc.M312372200.","journal-title":"J Biol Chem"},{"issue":"10","key":"4042_CR20","doi-asserted-by":"publisher","first-page":"3814","DOI":"10.1158\/1078-0432.CCR-04-2304","volume":"11","author":"M Ho","year":"2005","unstructured":"Ho M, Hassan R, Zhang J, Wang QC, Onda M, Bera T, Pastan I: Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients. Clin Cancer Res. 2005, 11 (10): 3814-3820. 10.1158\/1078-0432.CCR-04-2304.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"4042_CR21","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ejca.2007.08.028","volume":"44","author":"R Hassan","year":"2008","unstructured":"Hassan R, Ho M: Mesothelin targeted cancer immunotherapy. Eur J Cancer. 2008, 44 (1): 46-53. 10.1016\/j.ejca.2007.08.028.","journal-title":"Eur J Cancer"},{"issue":"2","key":"4042_CR22","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1097\/00000478-200302000-00002","volume":"27","author":"M Miettinen","year":"2003","unstructured":"Miettinen M, Sarlomo-Rikala M: Expression of calretinin, thrombomodulin, keratin 5, and mesothelin in lung carcinomas of different types: an immunohistochemical analysis of 596 tumors in comparison with epithelioid mesotheliomas of the pleura. Am J Surg Pathol. 2003, 27 (2): 150-158. 10.1097\/00000478-200302000-00002.","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"4042_CR23","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1158\/1535-7163.MCT-11-0454","volume":"11","author":"RJ Kelly","year":"2012","unstructured":"Kelly RJ, Sharon E, Pastan I, Hassan R: Mesothelin-targeted agents in clinical trials and in preclinical development. Mol Cancer Ther. 2012, 11 (3): 517-525. 10.1158\/1535-7163.MCT-11-0454.","journal-title":"Mol Cancer Ther"},{"issue":"23","key":"4042_CR24","doi-asserted-by":"publisher","first-page":"2678","DOI":"10.1002\/smll.201001447","volume":"6","author":"JL Steinbacher","year":"2010","unstructured":"Steinbacher JL, Lathrop SA, Cheng K, Hillegass JM, Butnor KJ, Kauppinen RA, Mossman BT, Landry CC: Gd-labeled microparticles in MRI: in vivo imaging of microparticles after intraperitoneal injection. Small. 2010, 6 (23): 2678-2682. 10.1002\/smll.201001447.","journal-title":"Small"},{"issue":"12","key":"4042_CR25","first-page":"3199","volume":"47","author":"FR Reale","year":"1987","unstructured":"Reale FR, Griffin TW, Compton JM, Graham S, Townes PL, Bogden A: Characterization of a human malignant mesothelioma cell line (H-MESO-1): a biphasic solid and ascitic tumor model. Cancer Res. 1987, 47 (12): 3199-3205.","journal-title":"Cancer Res"},{"issue":"1","key":"4042_CR26","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/ijc.25666","volume":"129","author":"JM Hillegass","year":"2011","unstructured":"Hillegass JM, Blumen SR, Cheng K, MacPherson MB, Alexeeva V, Lathrop SA, Beuschel SL, Steinbacher JL, Butnor KJ, Ramos-Nino ME, Shukla A, James TA, Weiss DJ, Taatjes DJ, Pass HI, Carbone M, Landry CC, Mossman BT: Increased efficacy of doxorubicin delivered in multifunctional microparticles for mesothelioma therapy. Int J Cancer. 2011, 129 (1): 233-244. 10.1002\/ijc.25666.","journal-title":"Int J Cancer"},{"key":"4042_CR27","volume-title":"Histotechnology: A Self-instructional Text","author":"FL Carson","year":"1997","unstructured":"Carson FL, Hladik C: Histotechnology: A Self-instructional Text. 1997, Chicago: ASCP Press, 96:"},{"issue":"5","key":"4042_CR28","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1016\/j.ajpath.2011.01.048","volume":"178","author":"T Sabo-Attwood","year":"2011","unstructured":"Sabo-Attwood T, Ramos-Nino ME, Eugenia-Ariza M, Macpherson MB, Butnor KJ, Vacek PC, McGee SP, Clark JC, Steele C, Mossman BT: Osteopontin modulates inflammation, mucin production, and gene expression signatures after inhalation of asbestos in a murine model of fibrosis. Am J Pathol. 2011, 178 (5): 1975-1985. 10.1016\/j.ajpath.2011.01.048.","journal-title":"Am J Pathol"},{"issue":"21","key":"4042_CR29","doi-asserted-by":"publisher","first-page":"9670","DOI":"10.1158\/0008-5472.CAN-05-1751","volume":"65","author":"A Haegens","year":"2005","unstructured":"Haegens A, van der Vliet A, Butnor KJ, Heintz N, Taatjes D, Hemenway D, Vacek P, Freeman BA, Hazen SL, Brennan ML, Mossman BT: Asbestos-induced lung inflammation and epithelial cell proliferation are altered in myeloperoxidase-null mice. Cancer Res. 2005, 65 (21): 9670-9677. 10.1158\/0008-5472.CAN-05-1751.","journal-title":"Cancer Res"},{"issue":"2","key":"4042_CR30","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1006\/abio.1998.2943","volume":"266","author":"P de Bruijn","year":"1999","unstructured":"de Bruijn P, Verweij J, Loos WJ, Kolker HJ, Planting AS, Nooter K, Stoter G, Sparreboom A: Determination of doxorubicin and doxorubicinol in plasma of cancer patients by high-performance liquid chromatography. Anal Biochem. 1999, 266 (2): 216-221. 10.1006\/abio.1998.2943.","journal-title":"Anal Biochem"},{"issue":"2","key":"4042_CR31","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1165\/rcmb.2009-0206TR","volume":"42","author":"NH Heintz","year":"2010","unstructured":"Heintz NH, Janssen-Heininger YM, Mossman BT: Asbestos, lung cancers, and mesotheliomas: from molecular approaches to targeting tumor survival pathways. Am J Respir Cell Mol Biol. 2010, 42 (2): 133-139. 10.1165\/rcmb.2009-0206TR.","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"12 Pt 1","key":"4042_CR32","doi-asserted-by":"publisher","first-page":"3937","DOI":"10.1158\/1078-0432.CCR-03-0801","volume":"10","author":"R Hassan","year":"2004","unstructured":"Hassan R, Bera T, Pastan I: Mesothelin: a new target for immunotherapy. Clin Cancer Res. 2004, 10 (12 Pt 1): 3937-3942.","journal-title":"Clin Cancer Res"},{"issue":"16","key":"4042_CR33","doi-asserted-by":"publisher","first-page":"5274","DOI":"10.1158\/1078-0432.CCR-09-0062","volume":"15","author":"RJ Kreitman","year":"2009","unstructured":"Kreitman RJ, Hassan R, Fitzgerald DJ, Pastan I: Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P. Clin Cancer Res. 2009, 15 (16): 5274-5279. 10.1158\/1078-0432.CCR-09-0062.","journal-title":"Clin Cancer Res"},{"issue":"17","key":"4042_CR34","doi-asserted-by":"publisher","first-page":"5144","DOI":"10.1158\/1078-0432.CCR-07-0869","volume":"13","author":"R Hassan","year":"2007","unstructured":"Hassan R, Bullock S, Premkumar A, Kreitman RJ, Kindler H, Willingham MC, Pastan I: Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res. 2007, 13 (17): 5144-5149. 10.1158\/1078-0432.CCR-07-0869.","journal-title":"Clin Cancer Res"},{"issue":"24","key":"4042_CR35","doi-asserted-by":"publisher","first-page":"6132","DOI":"10.1158\/1078-0432.CCR-10-2275","volume":"16","author":"R Hassan","year":"2010","unstructured":"Hassan R, Cohen SJ, Phillips M, Pastan I, Sharon E, Kelly RJ, Schweizer C, Weil S, Laheru D: Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers. Clin Cancer Res. 2010, 16 (24): 6132-6138. 10.1158\/1078-0432.CCR-10-2275.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"4042_CR36","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1158\/1078-0432.CCR-11-2121","volume":"18","author":"DT Le","year":"2012","unstructured":"Le DT, Brockstedt DG, Nir-Paz R, Hampl J, Mathur S, Nemunaitis J, Sterman DH, Hassan R, Lutz E, Moyer B, Giedlin M, Louis JL, Sugar EA, Pons A, Cox AL, Levine J, Murphy AL, Illei P, Dubensky TW, Eiden JE, Jaffee EM, Laheru DA: A Live-attenuated listeria vaccine (ANZ-100) and a live-attenuated listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction. Clin Cancer Res. 2012, 18 (3): 858-868. 10.1158\/1078-0432.CCR-11-2121.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"4042_CR37","doi-asserted-by":"publisher","first-page":"e33214","DOI":"10.1371\/journal.pone.0033214","volume":"7","author":"K Wang","year":"2012","unstructured":"Wang K, Bodempudi V, Liu Z, Borrego-Diaz E, Yamoutpoor F, Meyer A, Woo RA, Pan W, Dudek AZ, Olyaee MS, Esfandyari T, Farassati F: Inhibition of mesothelin as a novel strategy for targeting cancer cells. PLoS One. 2012, 7 (4): e33214-10.1371\/journal.pone.0033214.","journal-title":"PLoS One"},{"issue":"2","key":"4042_CR38","doi-asserted-by":"publisher","first-page":"e84","DOI":"10.3747\/co.v18i2.663","volume":"18","author":"F Mohamed","year":"2011","unstructured":"Mohamed F, Cecil T, Moran B, Sugarbaker P: A new standard of care for the management of peritoneal surface malignancy. Curr Oncol. 2011, 18 (2): e84-96.","journal-title":"Curr Oncol"},{"issue":"2","key":"4042_CR39","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1245\/s10434-006-9182-x","volume":"14","author":"TD Yan","year":"2007","unstructured":"Yan TD, Black D, Savady R, Sugarbaker PH: A systematic review on the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann Surg Oncol. 2007, 14 (2): 484-492. 10.1245\/s10434-006-9182-x.","journal-title":"Ann Surg Oncol"},{"issue":"36","key":"4042_CR40","doi-asserted-by":"publisher","first-page":"6237","DOI":"10.1200\/JCO.2009.23.9640","volume":"27","author":"TD Yan","year":"2009","unstructured":"Yan TD, Deraco M, Baratti D, Kusamura S, Elias D, Glehen O, Gilly FN, Levine EA, Shen P, Mohamed F, Moran BJ, Morris DL, Chua TC, Piso P, Sugarbaker PH: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009, 27 (36): 6237-6242. 10.1200\/JCO.2009.23.9640.","journal-title":"J Clin Oncol"},{"key":"4042_CR41","first-page":"471205","volume":"2012","author":"PH Sugarbaker","year":"2012","unstructured":"Sugarbaker PH, Stuart OA, Eger C: Pharmacokinetics of hyperthermic intrathoracic chemotherapy following pleurectomy and decortication. Gastroenterol Res Pract. 2012, 2012: 471205-","journal-title":"Gastroenterol Res Pract"},{"issue":"6","key":"4042_CR42","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/jlb.66.6.889","volume":"66","author":"JS Lewis","year":"1999","unstructured":"Lewis JS, Lee JA, Underwood JC, Harris AL, Lewis CE: Macrophage responses to hypoxia: relevance to disease mechanisms. J Leukoc Biol. 1999, 66 (6): 889-900.","journal-title":"J Leukoc Biol"},{"issue":"3","key":"4042_CR43","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s10555-006-9001-7","volume":"25","author":"A Mantovani","year":"2006","unstructured":"Mantovani A, Schioppa T, Porta C, Allavena P, Sica A: Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev. 2006, 25 (3): 315-322. 10.1007\/s10555-006-9001-7.","journal-title":"Cancer Metastasis Rev"},{"issue":"1","key":"4042_CR44","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.semcancer.2005.07.006","volume":"16","author":"A Ben-Baruch","year":"2006","unstructured":"Ben-Baruch A: Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators. Semin Cancer Biol. 2006, 16 (1): 38-52. 10.1016\/j.semcancer.2005.07.006.","journal-title":"Semin Cancer Biol"},{"issue":"5","key":"4042_CR45","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1189\/jlb.0609385","volume":"86","author":"G Solinas","year":"2009","unstructured":"Solinas G, Germano G, Mantovani A, Allavena P: Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol. 2009, 86 (5): 1065-1073. 10.1189\/jlb.0609385.","journal-title":"J Leukoc Biol"},{"issue":"1","key":"4042_CR46","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/nrc704","volume":"2","author":"AL Harris","year":"2002","unstructured":"Harris AL: Hypoxia\u2013a key regulatory factor in tumour growth. Nat Rev Cancer. 2002, 2 (1): 38-47. 10.1038\/nrc704.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"4042_CR47","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.lungcan.2005.07.010","volume":"51","author":"A Klabatsa","year":"2006","unstructured":"Klabatsa A, Sheaff MT, Steele JP, Evans MT, Rudd RM, Fennell DA: Expression and prognostic significance of hypoxia-inducible factor 1alpha (HIF-1alpha) in malignant pleural mesothelioma (MPM). Lung Cancer. 2006, 51 (1): 53-59. 10.1016\/j.lungcan.2005.07.010.","journal-title":"Lung Cancer"},{"issue":"24 Pt 1","key":"4042_CR48","doi-asserted-by":"publisher","first-page":"8782","DOI":"10.1158\/1078-0432.CCR-05-1664","volume":"11","author":"AJ Primeau","year":"2005","unstructured":"Primeau AJ, Rendon A, Hedley D, Lilge L, Tannock IF: The distribution of the anticancer drug Doxorubicin in relation to blood vessels in solid tumors. Clin Cancer Res. 2005, 11 (24 Pt 1): 8782-8788.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"4042_CR49","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1023\/A:1025785505977","volume":"20","author":"SH Jang","year":"2003","unstructured":"Jang SH, Wientjes MG, Lu D, Au JL: Drug delivery and transport to solid tumors. Pharm Res. 2003, 20 (9): 1337-1350. 10.1023\/A:1025785505977.","journal-title":"Pharm Res"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-13-400.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-13-400\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-13-400","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-13-400.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T01:19:17Z","timestamp":1630545557000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-13-400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,11]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["4042"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-13-400","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,11]]},"assertion":[{"value":"16 November 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"400"}}